Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin.
Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin.
复制标题
DOI：
10.1097/01.pra.0000265763.79753.c1
复制
发表时间：
2007-03-01
影响因子：
1.9
通讯作者：
Kinzie, J David
中科院分区：
文献类型：
--
作者：
Boehnlein, James K;Kinzie, J David
本文回顾了使用减少中枢神经系统去甲肾上腺素能药物治疗创伤后应激障碍侵入性症状的神经生物学原理，并提出了临床指导。作者回顾了神经生物学研究、使用动物模型的非临床研究、临床病例报告、开放标签药物研究以及盲法安慰剂对照药物研究。对基础科学和临床文献的回顾，以及作者对不同文化和人口统计人群的临床经验表明，可乐定和哌唑嗪可以在治疗创伤后应激障碍的睡眠障碍和过度警觉方面发挥有用的作用，且副作用最小，经济成本低。
This article reviews the neurobiologic rationale for and presents clinical guidance concerning the use of medications that reduce central nervous system noradrenergic activity in the treatment of intrusive symptoms of posttraumatic stress disorder. The authors reviewed neurobiological studies, nonclinical studies using animal models, clinical case reports, open-label drug studies, and blinded, placebo-controlled drug studies. This review of the basic science and clinical literature, and the authors' clinical experience with culturally and demographically diverse populations, indicate that clonidine and prazosin can play a useful role in treating sleep disturbance and hyperarousal in posttraumatic stress disorder, with minimal adverse effects and low financial cost.